Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

View Full Paper
Ask AI
Bookmark
Share

Authors

PLPeihua LuSinopec (China)YHYongxian HuZhejiang Chinese Medical UniversityXZXian ZhangNanjing University of Chinese Medicine

Discussion

Loading...

Member takes

Implication

Phase I/II trials find 64.1% remission in relapsed/refractory acute lymphoblastic leukemia, suggesting effective CAR T-cell therapy.

Key Points

  • To evaluate the safety and efficacy of CTD402 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoma.
  • Conducted Phase I/II trials across 9 centers in China
  • Administered CTD402 at a recommended phase 2 dose of 400 million cells after lymphodepleting chemotherapy
  • Assessed clinical outcomes including cytokine release syndrome and remission rates.
  • 64.1% complete remission rate achieved in evaluable patients
  • Cytokine release syndrome occurred in 78% of patients, primarily mild
  • Cytopenia was common, with neutrophil counts recovering by day 21.

Cite This Study

Lu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d468https://doi.org/10.1182/blood-2025-1042
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)2025
  2. 2Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.2024 · 3 citations
  3. 3Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies2025
  4. 4CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL2016 · 41 citations
  5. 5A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia2025